Ignite Creation Date:
2024-05-06 @ 10:47 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03358472
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2017-11-27
Brief Title:
Pembrolizumab Plus Epacadostat Pembrolizumab Monotherapy and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma KEYNOTE-669ECHO-304
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation